Dirk Jäger

Dirk Jäger

UNVERIFIED PROFILE

Are you Dirk Jäger?   Register this Author

Register author
Dirk Jäger

Dirk Jäger

Publications by authors named "Dirk Jäger"

Are you Dirk Jäger?   Register this Author

48Publications

1294Reads

24Profile Views

Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology.

Cancer Res 2019 Oct 10;79(19):4801-4807. Epub 2019 Jul 10.

Pennsylvania Cancer and Regenerative Medicine Research Center, Baruch S. Blumberg Institute, Pennsylvania Biotechnology Center, Wynnewood, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-19-1167DOI Listing
October 2019

Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer: current knowledge and future perspectives.

Expert Rev Anticancer Ther 2019 Jan 29;19(1):29-42. Epub 2018 Oct 29.

a National Center for Tumor Diseases, Department of Medical Oncology , University of Heidelberg , Heidelberg , Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2019.1537785DOI Listing
January 2019

Genomics and emerging biomarkers for immunotherapy of colorectal cancer.

Semin Cancer Biol 2018 10 1;52(Pt 2):189-197. Epub 2018 Mar 1.

Department of Medical Oncology and Internal Medicine VI, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany; Applied Tumor Immunity, German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S1044579X173025
Publisher Site
http://dx.doi.org/10.1016/j.semcancer.2018.02.010DOI Listing
October 2018

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.

J Clin Oncol 2018 10 15;36(28):2836-2844. Epub 2018 Aug 15.

Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.6212DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161834PMC
October 2018

High-Throughput Screening of Combinatorial Immunotherapies with Patient-Specific Models of Metastatic Colorectal Cancer.

Cancer Res 2018 09 2;78(17):5155-5163. Epub 2018 Jul 2.

Department of Medical Oncology and Internal Medicine VI, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-54
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-18-1126DOI Listing
September 2018

Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors.

Clin Cancer Res 2018 05 6;24(9):2128-2137. Epub 2018 Feb 6.

Department of Translational Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-2651DOI Listing
May 2018

Randomized controlled trial of S-1 maintenance therapy in metastatic esophagogastric cancer - the multinational MATEO study.

BMC Cancer 2017 Jul 31;17(1):509. Epub 2017 Jul 31.

University Cancer Center Leipzig (UCCL), University Hospital Leipzig, Liebigstrasse 20, D-04103, Leipzig, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-017-3497-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537937PMC
July 2017

Detailed resolution analysis reveals spatial T cell heterogeneity in the invasive margin of colorectal cancer liver metastases associated with improved survival.

Oncoimmunology 2017 23;6(3):e1286436. Epub 2017 Feb 23.

Department of Medical Oncology, National Center for Tumor Diseases (NCT) and University Hospital Heidelberg , Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2017.1286436DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384380PMC
February 2017

Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.

J Clin Oncol 2017 Jan 31;35(1):40-47. Epub 2016 Oct 31.

Tomasz M. Beer, Oregon Health and Science University, Portland, OR; Eugene D. Kwon, Mayo Clinic, Rochester, MN; Charles G. Drake, Johns Hopkins University, Baltimore, MD; Karim Fizazi, University of Paris-Sud, Villejuif; Gwenaelle Gravis, Institut Paoli-Calmettes, Marseille, France; Christopher Logothetis, University of Texas MD Anderson Cancer Center, Houston, TX; Vinod Ganju, Monash University, Melbourne, Victoria; Siobhan S. Ng, St John of God Hospital, Subiaco, Western Australia; Francis X. Parnis, Adelaide Cancer Centre, Adelaide, South Australia, Australia; Jonathan Polikoff, Southern California Permanente Medical Group, San Marcos, CA; Fred Saad, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada; Piotr Humanski, Niepubliczny Zaklad Opieki Zdrowotnej Specjalista, Kutno, Poland; Josep M. Piulats, Institut Català d'Oncologia, Barcelona; Javier Puente, Hospital Clínico San Carlos, Madrid, Spain; Pablo Gonzalez Mella, Instituto Oncologico, Viña del Mar; Pablo Gonzalez Mella, Fundación Arturo Lopez Pérez, Santiago, Chile; Dirk Jaeger, University Hospital, Heidelberg, Germany; Fabio A. Franke, Hospital de Caridade de Ijuí, Ijuí, Brazil; Roman Carvajal, Hospital Regional Valentin Gomez Farias, Zapopan, Mexico; Lisa Sengeløv, Herlev Hospital, Herlev, Denmark; M. Brent McHenry, Bristol-Myers Squibb, Wallingford, CT; Arvind Varma, DOCS Inc, New York, NY; Alfonsus J. van den Eertwegh, VU University Medical Center, Amsterdam; and Winald Gerritsen, Radboud University, Nijmegen, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.1584DOI Listing
January 2017

Bcl-xL is an oncogenic driver in colorectal cancer.

Cell Death Dis 2016 08 18;7(8):e2342. Epub 2016 Aug 18.

National Center for Tumor Diseases, Department of Medical Oncology and Heidelberg University Hospital, Internal Medicine VI, 69120 Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/cddis.2016.233DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108319PMC
August 2016

Exercise and cancer: return to work as a firefighter with ostomy after rectal carcinoma - a case report.

Medicine (Baltimore) 2016 Jul;95(29):e4309

aDepartment of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg bDepartment of Sports Medicine, Heidelberg University Hospital, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000004309DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5265794PMC
July 2016

Pan-Bcl-2 inhibitor obatoclax delays cell cycle progression and blocks migration of colorectal cancer cells.

PLoS One 2014 5;9(9):e106571. Epub 2014 Sep 5.

National Center for Tumor Diseases, Department of Medical Oncology, Internal Medicine VI, Heidelberg University Hospital, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0106571PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4156353PMC
March 2016

Nuclear expression of the deubiquitinase CYLD is associated with improved survival in human hepatocellular carcinoma.

PLoS One 2014 16;9(10):e110591. Epub 2014 Oct 16.

National Center for Tumor Diseases, Department of Medical Oncology, Internal Medicine VI, Heidelberg University Hospital, Heidelberg, Germany; Department of Gastroenterology, Diabetology and Rheumatology, Internal Medicine II, Marien-Hospital, Wesel, Germany.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0110591PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199737PMC
December 2015

Outcomes and risk factors for cancer patients undergoing endoscopic intervention of malignant biliary obstruction.

BMC Gastroenterol 2015 Dec 4;15:171. Epub 2015 Dec 4.

Department of Gastroenterology, Toxicology and Infectious Diseases, University Hospital Heidelberg, Im Neuenheimer Feld 410, Heidelberg, 69120, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12876-015-0399-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670509PMC
December 2015

Efficacy of nab-paclitaxel does not seem to be associated with SPARC expression in metastatic breast cancer.

Anticancer Res 2014 Nov;34(11):6609-15

National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany Department of Gynecology and Obstetrics, University Hospital Heidelberg, Heidelberg, Germany.

View Article

Download full-text PDF

Source
November 2014

Nab-Paclitaxel monotherapy as a treatment of patients with metastatic breast cancer in routine clinical practice.

Anticancer Res 2013 Aug;33(8):3407-13

National Center for Tumor Diseases, University Hospital, Im Neuenheimer Feld 460, D-69120 Heidelberg, Germany.

View Article

Download full-text PDF

Source
August 2013

Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine.

Hum Gene Ther 2013 Jul;24(7):644-54

Department of Translational Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ) , D-69120 Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/hum.2012.205DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3719441PMC
July 2013

Hepatic metastases of colorectal cancer are rather homogeneous but differ from primary lesions in terms of immune cell infiltration.

Oncoimmunology 2013 Apr;2(4):e24116

National Center for Tumor Diseases; Medical Oncology and Internal Medicine VI; University Hospital Heidelberg; Heidelberg, Germany ; Tissue Imaging and Analysis Center (TIGA); BIOQUANT; Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/onci.24116DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654605PMC
April 2013

Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma.

Oncology 2013 13;84(1):6-13. Epub 2012 Oct 13.

Department of Internal Medicine, University of Heidelberg, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000342425DOI Listing
January 2013

Posterior reversible leukoencephalopathy syndrome associated with pazopanib.

Case Rep Oncol 2013 Jan 6;6(1):204-8. Epub 2013 Apr 6.

Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000350742DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3636956PMC
January 2013

Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.

Expert Opin Pharmacother 2012 Mar 13;13(4):473-94. Epub 2012 Feb 13.

National Center for Tumor Diseases (NCT)/ University of Heidelberg, and German Cancer Research Center (DKFZ), Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1517/14656566.2012.65
Publisher Site
http://dx.doi.org/10.1517/14656566.2012.656091DOI Listing
March 2012

The local immunological microenvironment in colorectal cancer as a prognostic factor for treatment decisions in the clinic: The way ahead.

Oncoimmunology 2012 Jan;1(1):62-66

National Center for Tumor Diseases; Department of Medical Oncology; University of Heidelberg; Heidelberg, Germany ; Hamamatsu Tissue Imaging and Analysis Center; University of Heidelberg; Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/abs/10.4161/onci.1.1.18460
Publisher Site
http://dx.doi.org/10.4161/onci.1.1.18460DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3376959PMC
January 2012

Targeting the tumor microenvironment: focus on angiogenesis.

J Oncol 2012 24;2012:281261. Epub 2011 Aug 24.

Medical Oncology, National Center for Tumor Diseases (NCT), University of Heidelberg and German Cancer Research Center (DKFZ), Im Neuenheimer Feld 460, 69120 Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2012/281261DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3163131PMC
November 2011

Renal cell cancer--a multimodal approach to preserving renal function and improving survival.

Nephrol Dial Transplant 2011 Oct 28;26(10):3086-8. Epub 2011 May 28.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ndt/gfr268DOI Listing
October 2011

Advanced malignant melanoma: immunologic and multimodal therapeutic strategies.

J Oncol 2010 9;2010:689893. Epub 2010 Mar 9.

National Center for Tumor Diseases, Department of Medical Oncology, University of Heidelberg, 69120 Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2010/689893DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2836142PMC
July 2011

Neoadjuvant treatment does not influence perioperative outcome in rectal cancer surgery.

Int J Radiat Oncol Biol Phys 2009 Sep 21;75(1):129-36. Epub 2009 Mar 21.

Department of Surgery, University of Heidelberg, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S036030160803732
Publisher Site
http://dx.doi.org/10.1016/j.ijrobp.2008.10.051DOI Listing
September 2009

Treatment with cetuximab, bevacizumab and irinotecan in heavily pretreated patients with metastasized colorectal cancer.

Anticancer Res 2008 Nov-Dec;28(6B):4111-5

National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany.

View Article

Download full-text PDF

Source
February 2009

Cancer testis antigen expression in gastrointestinal stromal tumors: new markers for early recurrence.

Int J Cancer 2008 Oct;123(7):1551-5

Department of Visceral and Transplant Surgery, University Hospital Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.23698DOI Listing
October 2008

Short time to progression under first-line chemotherapy is a negative prognostic factor for time to progression and residual survival under second-line chemotherapy in advanced pancreatic cancer.

Oncology 2007 23;73(5-6):335-9. Epub 2008 May 23.

Department of Medical Oncology, National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000134477DOI Listing
August 2008

Protein S100 as prognostic marker for gastrointestinal stromal tumors: a clinicopathological risk factor analysis.

J Invest Surg 2007 May-Jun;20(3):181-6

Department of Visceral and Transplantation Surgery, University Hospital Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1080/0894193070136634
Publisher Site
http://dx.doi.org/10.1080/08941930701366349DOI Listing
August 2007

Real-time definition of non-randomness in the distribution of genomic events.

PLoS One 2007 Jun 27;2(6):e570. Epub 2007 Jun 27.

Department of Translational Oncology, National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany; Department of Medical Biostatistics, Tumor Center Heidelberg-Mannheim, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0000570PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1892803PMC
June 2007

Melanocyte differentiation antigen RAB38/NY-MEL-1 induces frequent antibody responses exclusively in melanoma patients.

Cancer Immunol Immunother 2007 Feb 23;56(2):249-58. Epub 2006 May 23.

Klinik und Poliklinik für Onkologie, Departement für Innere Medizin, UniversitätsSpital Zürich, Rämistrasse 100, 8091 Zürich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-006-0177-zDOI Listing
February 2007